Source: Annual Congress 2010 - Pulmonary infections and sepsis
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
O. Rosenberg, A. Alekseev, I. Alexey, S. Marina, S. Andrey, V. Vladimir (St. Petersberg, , Tumen, Russian Federation). Surfactant therapy of A/H1N1 severe pneumonia and ARDS is a chance for survival. Eur Respir J 2010; 36: Suppl. 54, 4261

Member's Comments

No comment yet.

Related content which might interest you: Peculiarities of an ARDS and respiratory support in patients with severe viral (H1N1) pneumonia Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Surfactant treatment leads to a sustained improvement of oxygenation only in severe pediatric ARDS without pneumonia Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Arterial hypoxemia and diminished immune response at admission predict poor outcome in patients with viral-bacterial pneumonia during flu H1N1 pandemic period Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia Source: ERJ Open Res, 7 (1) 00888-2020; 10.1183/23120541.00888-2020 Year: 2021 Comparison of H1N1 associated pneumonia with community acquired pneumonia in hospitalized patients Source: Annual Congress 2010 - Influenza A (H1N1): characteristics, risk factors and prognosis Year: 2010 Sepsis severity is an excellent predictor of mortality in pneumococcal pneumonia Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Influenza vaccination is associated with reduced severity of community-acquired pneumonia Source: Eur Respir J 2011; 37: 147-153 Year: 2011 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Non-invasive ventilation (NIV) in community-acquired pneumonia CAP) and severe acute respiratory failure (ARF): Effectiveness and risk factors for failure and mortality Source: Annual Congress 2011 - Recent advances in noninvasive ventilation used for treating acute respiratory failure Year: 2011 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 The application of bi-level positive airway pressure in patients with severe pneumonia and acute respiratory failure caused by influenza A (H1N1) virus Source: Annual Congress 2011 - Noninvasive ventilation in the acute setting: education, organisation, H1N1, paediatrics, weaning, diagnostic procedures and special considerations Year: 2011 Early corticosteroid in influenza pneumonia related acute respiratory distress syndrome treated with extracorporeal membrane oxygenation Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018 COPD is associated with increased mortality in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: 346-351 Year: 2006 Surfactant therapy for persistent atelectasis developed in the children with acute bronchopneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 629s Year: 2005 Prediction of complications development and lethal outcome in patients with community-acquired pneumonia Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011